These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 31149444

  • 1. Pathological response of salivary duct carcinoma to trastuzumab and docetaxel therapy.
    Ueki Y, Tada Y, Togashi T, Kawakita D, Nagao T, Sato Y.
    Int Cancer Conf J; 2016 Jul; 5(3):150-153. PubMed ID: 31149444
    [Abstract] [Full Text] [Related]

  • 2. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.
    Park JC, Ma TM, Rooper L, Hembrough T, Foss RD, Schmitt NC, Sawhney R, Flanders A, Kang H.
    Head Neck; 2018 Dec; 40(12):E100-E106. PubMed ID: 30478962
    [Abstract] [Full Text] [Related]

  • 3. Treatment of HER2+ metastatic salivary ductal carcinoma in a pregnant woman: a case report.
    Bergamini C, Cavalieri S, Sanguineti G, Farneti A, Licitra L.
    Oxf Med Case Reports; 2019 Oct; 2019(10):omz102. PubMed ID: 31772741
    [Abstract] [Full Text] [Related]

  • 4. Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma.
    Kadowaki S, Yatabe Y, Hirakawa H, Komori A, Kondoh C, Hasegawa Y, Muro K.
    Case Rep Oncol; 2013 Oct; 6(3):450-5. PubMed ID: 24163659
    [Abstract] [Full Text] [Related]

  • 5. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.
    Boon E, Bel M, van Boxtel W, van der Graaf WTA, van Es RJJ, Eerenstein SEJ, Baatenburg de Jong RJ, van den Brekel MWM, van der Velden LA, Witjes MJH, Hoeben A, Willems SM, Bloemena E, Smit LA, Oosting SF, PALGA Group, Jonker MA, Flucke UE, van Herpen CML.
    Int J Cancer; 2018 Aug 15; 143(4):758-766. PubMed ID: 29492965
    [Abstract] [Full Text] [Related]

  • 6. Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report.
    Kawahara K, Hiraki A, Yoshida R, Arita H, Matsuoka Y, Yamashita T, Koga KI, Nagata M, Hirosue A, Fukuma D, Nakayama H.
    Mol Clin Oncol; 2017 Jun 15; 6(6):886-892. PubMed ID: 28588783
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report.
    Yang ZY, Huang JH, Chen B, Xu CW, Lei L, Wang XJ, Fang MY.
    Front Oncol; 2020 Jun 15; 10():559057. PubMed ID: 33123470
    [Abstract] [Full Text] [Related]

  • 8. Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature.
    Krishnamurthy J, Krishnamurty DM, Baker JJ, Zhen W, Lydiatt D, Ganti AK.
    Head Neck; 2013 Dec 15; 35(12):E372-5. PubMed ID: 23765450
    [Abstract] [Full Text] [Related]

  • 9. HER2/HER3-positive metastatic salivary duct carcinoma in the pleural effusion: A case report.
    Murata K, Kawahara A, Ono T, Takase Y, Abe H, Naito Y, Akiba J.
    Diagn Cytopathol; 2018 May 15; 46(5):429-433. PubMed ID: 29205961
    [Abstract] [Full Text] [Related]

  • 10. Macrocystic and non-necrotic salivary duct carcinoma of the submandibular gland: A case report.
    Yorita K, Miyazaki K, Urano M, Nagao T, Nakaguro M, Tahara K, Takeda T, Nakatani K.
    Radiol Case Rep; 2024 Aug 15; 19(8):3049-3055. PubMed ID: 38756951
    [Abstract] [Full Text] [Related]

  • 11. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy.
    Prat A, Parera M, Reyes V, Peralta S, Cedrés S, Andreu J, Huguet P, del Campo JM.
    Head Neck; 2008 May 15; 30(5):680-3. PubMed ID: 17972317
    [Abstract] [Full Text] [Related]

  • 12. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupré PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, Berriolo-Riedinger A.
    Lancet Oncol; 2014 Dec 15; 15(13):1493-1502. PubMed ID: 25456368
    [Abstract] [Full Text] [Related]

  • 13. Metastatic salivary duct carcinoma in cardiac and pleural effusions: A case report with immunocytochemical analysis for androgen receptor and HER2.
    Ito H, Ishida M, Sando K, Okano K, Ebisu Y, Fujisawa T, Iwai H, Tsuta K.
    Mol Clin Oncol; 2019 Jan 15; 10(1):78-82. PubMed ID: 30655980
    [Abstract] [Full Text] [Related]

  • 14. Metastatic Salivary Duct Carcinoma with ERBB2 Amplification and Sequential Response to Ado-Trastuzumab Emtansine and Neratinib: A Case Report.
    Asper N, Roth KS, Hany TF, Salzberg SP, Tinguely M, Kadvany Y, Trojan A.
    Case Rep Oncol; 2023 Jan 15; 16(1):1500-1507. PubMed ID: 38033416
    [Abstract] [Full Text] [Related]

  • 15. Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.
    Takahashi H, Tada Y, Saotome T, Akazawa K, Ojiri H, Fushimi C, Masubuchi T, Matsuki T, Tani K, Osamura RY, Hirai H, Yamada S, Kawakita D, Miura K, Kamata SE, Nagao T.
    J Clin Oncol; 2019 Jan 10; 37(2):125-134. PubMed ID: 30452336
    [Abstract] [Full Text] [Related]

  • 16. Sustained response of HER2-positive metastatic salivary adenocarcinoma, not otherwise specified, treated with trastuzumab.
    Ghazali N, Parker L, Settle K, Lubek JE.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Sep 10; 122(3):292-9. PubMed ID: 27289263
    [Abstract] [Full Text] [Related]

  • 17. The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy.
    Saigusa N, Hirai H, Tada Y, Kawakita D, Nakaguro M, Tsukahara K, Kano S, Ozawa H, Kondo T, Okami K, Togashi T, Sato Y, Urano M, Kajiwara M, Shimura T, Fushimi C, Shimizu A, Okamoto I, Okada T, Suzuki T, Imanishi Y, Watanabe Y, Sakai A, Ebisumoto K, Sato Y, Honma Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Takahashi H, Ando M, Kohsaka S, Matsuki T, Nagao T.
    Front Oncol; 2021 Sep 10; 11():779882. PubMed ID: 35186711
    [Abstract] [Full Text] [Related]

  • 18. Breast metastasis of salivary duct carcinoma in a patient: a case report.
    Guo S, Yao J.
    Int J Clin Exp Med; 2015 Sep 10; 8(11):21765-9. PubMed ID: 26885140
    [Abstract] [Full Text] [Related]

  • 19. Successful multimodal treatment of intraoral salivary duct carcinoma in a patient with multiple lymph node metastases: a case report.
    Imaue S, Tomihara K, Hamashima T, Tomizawa G, Nomura K, Sasahara M, Noguchi M.
    World J Surg Oncol; 2017 Jan 10; 15(1):18. PubMed ID: 28073374
    [Abstract] [Full Text] [Related]

  • 20. Salivary Duct Carcinoma with Late Distant Brain and Cutaneous Metastasis: A Case Report.
    Mirmohammad Sadeghi H, Karimi A, Rahpeima A, Derakhshan S.
    Iran J Pathol; 2020 Jan 10; 15(3):521-525. PubMed ID: 32754223
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.